Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
30
Recruiting, industry sponsors, Kidney and urology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed344
30 trials
Showing 1 to 25, recently updated first.
- A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving HemodialysisPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT03969329 · 24 participants (planned) · Start Dec 20, 2019 · Primary completion Jun 30, 2027
Drug: Etelcalcetide · For: Secondary Hyperparathyroidism
Sites: Ghent, Belgium; Prague, Czechia; Bron, France · 23 sites in all
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07850752 · 340 participants (planned) · Start Nov 11, 2026 · Primary completion Sep 17, 2028
Drug: zigakibart; atrasentan and 1 more · For: IgA Nephropathy (IgAN)
Sites: Huntsville, Alabama; Fremont, California; Newark, Delaware · 11 sites in all
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringePivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07890909 · 40 participants (planned) · Start Nov 13, 2026 · Primary completion Dec 12, 2027
Drug: Povetacicept; Sibeprenlimab · For: Immunoglobulin A Nephropathy
Sites: Orlando, Florida; Lawrenceville, Georgia
- A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Pivotal-lookingRecruiting
Kind Pharmaceuticals LLCIndustry
NCT07487727 · 240 participants (planned) · Start Dec 3, 2025 · Primary completion Mar 1, 2027
Drug: AND017; ESA · For: Anemia Due to Chronic Kidney Disease
Sites: Beijing, China
- Study of Ravulizumab in Pediatric Participants With Primary IgANPivotal-lookingRecruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT07024563 · 36 participants (planned) · Start Jun 14, 2025 · Primary completion Nov 29, 2028
Drug: Ravulizumab · For: IgAN; IgAVN; Immunoglobulin A Nephropathy and 3 more
Sites: Palo Alto, California; Aurora, Colorado; London, Canada · 19 sites in all
- A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)Pivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07220083 · 286 participants (planned) · Start Feb 16, 2026 · Primary completion Dec 27, 2028
Drug: BI 764198; Placebo · For: Focal Segmental Glomerulosclerosis
Sites: Alabaster, Alabama; Huntsville, Alabama; Surprise, Arizona · 309 sites in all
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressurePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06742723 · 5,000 participants (planned) · Start Mar 3, 2025 · Primary completion Dec 18, 2029
Drug: Baxdrostat/dapagliflozin; Placebo/dapagliflozin · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Sun City, Arizona; Tucson, Arizona · 771 sites in all
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07498335 · 28 participants (planned) · Start Aug 6, 2026 · Primary completion Sep 15, 2031
Drug: Drug: Atrasentan · For: Berger Disease; Bergers Disease; IgA Nephropathy and 3 more
Sites: Neptune City, New Jersey; Cincinnati, Ohio; Oklahoma City, Oklahoma · 23 sites in all
- Study of MT1013 for the Treatment of Patients With Secondary HyperparathyroidismPivotal-lookingRecruiting
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT07122401 · 424 participants (planned) · Start Sep 30, 2025 · Primary completion Nov 26, 2026
Drug: MT1013; Cinacalcet · For: Secondary Hyperparathyroidism, Chronic Kidney Disease
Sites: Shanghai, China
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07241390 · 7,140 participants (planned) · Start Dec 1, 2025 · Primary completion Aug 2031
Drug: Orforglipron; Placebo · For: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; C.a.b.a., Argentina · 566 sites in all
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06963827 · 347 participants (planned) · Start Jul 15, 2025 · Primary completion Sep 7, 2028
Drug: Mezagitamab; Placebo · For: Kidney Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Surprise, Arizona · 186 sites in all
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyPivotal-lookingRecruiting
Jade Biosciences, Inc.Industry
NCT07902817 · 480 participants (planned) · Start Dec 2026 · Primary completion Jun 2029
Drug: JADE101; Placebo · For: IgA Nephropathy (IgAN)
Sites: Arvada, Colorado; Lauderdale Lakes, Florida; Atlanta, Georgia · 4 sites in all
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT06935357 · 454 participants (planned) · Start May 8, 2025 · Primary completion May 31, 2027
Drug: Felzartamab; Placebo · For: Immunoglobulin A Nephropathy (IgAN)
Sites: Little Rock, Arkansas; Apple Valley, California; Carlsbad, California · 265 sites in all
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04557462 · 540 participants (planned) · Start Sep 20, 2021 · Primary completion Dec 4, 2030
Drug: LNP023 · For: Primary IgA Nephropathy
Sites: Glendale, Arizona; San Diego, California; San Dimas, California · 161 sites in all
- A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07624305 · 2,800 participants (planned) · Start Sep 1, 2026 · Primary completion Jul 1, 2030
Drug: Balcinrenone/dapagliflozin; Dapagliflozin and 2 more · For: Renal Insufficiency, Chronic
Sites: Huntsville, Alabama; Surprise, Arizona; Tempe, Arizona · 478 sites in all
BayerBayer (BAYRY)
NCT05457283 · 100 participants (planned) · Start Nov 8, 2022 · Primary completion Aug 7, 2028
Drug: Finerenone (Kerendia, BAY94-8862) · For: Chronic Kidney Disease; Proteinuria; Children
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 151 sites in all
- A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07753993 · 7,000 participants (planned) · Start Aug 21, 2026 · Primary completion Oct 4, 2030
Drug: Elecoglipron; Placebo · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Montgomery, Alabama; Sheffield, Alabama · 715 sites in all
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06994845 · 31 participants (planned) · Start Nov 27, 2025 · Primary completion Jun 28, 2030
Drug: iptacopan · For: Primary Immunoglobulin A Nephropathy (IgAN)
Sites: Madera, California; Aurora, Colorado; Gainesville, Florida · 20 sites in all
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07662135 · 900 participants (planned) · Start Jul 6, 2026 · Primary completion Jul 13, 2028
Drug: Elecoglipron; Placebo · For: Type 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease
Sites: Sun City, Arizona; Surprise, Arizona; Concord, California · 186 sites in all
- A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental GlomerulosclerosisPivotal-lookingRecruiting
Apellis Pharmaceuticals, Inc.Industry
NCT07213960 · 270 participants (planned) · Start Dec 2026 · Primary completion Oct 2029
Drug: APL2 · For: FSGS
Sites: Chicago, Illinois; New York, New York
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06858319 · 220 participants (planned) · Start Jul 28, 2025 · Primary completion Jun 25, 2031
Drug: zigakibart · For: Kidney Diseases; Kidney Diseases, Chronic; Urological Diseases and 5 more
Sites: Denver, Colorado; Orlando, Florida; Iowa City, Iowa · 26 sites in all
- A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney DiseasePivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07419828 · 5,386 participants (planned) · Start Mar 13, 2026 · Primary completion Apr 2030
Drug: HRS-1780 tablets; Placebo · For: Chronic Kidney Disease
Sites: Nanjing, China
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07390123 · 370 participants (planned) · Start Apr 7, 2026 · Primary completion Dec 2027
Drug: HSK39297; Placebo · For: IgA Nephropathy (IgAN)
Sites: Huangshan City, China; Wuhu, China; Beijing, China · 9 sites in all
- A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisPivotal-lookingRecruiting
Genexine, Inc.Industry
NCT06466785 · 429 participants (planned) · Start Jan 25, 2024 · Primary completion Jun 2027
Drug: Efepoetin Alfa; Darbepoetin Alfa · For: Anemia of Chronic Kidney Disease
Sites: Yerevan, Armenia; Blagoevgrad, Bulgaria; Dobrich, Bulgaria · 58 sites in all
- A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)Pivotal-lookingRecruiting
AMAG Pharmaceuticals, Inc.Industry
NCT03619850 · 129 participants (planned) · Start Aug 13, 2018 · Primary completion Aug 31, 2026
Drug: Ferumoxytol; Iron sucrose · For: Chronic Kidney Disease; Iron Deficiency Anemia
Sites: Hollywood, Florida; Detroit, Michigan; Kansas City, Missouri · 21 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.